Technical Analysis for ADGI - Adagio Therapeutics, Inc.

Grade Last Price % Change Price Change
F 5.6 1.82% 0.10
ADGI closed down 3.51 percent on Tuesday, January 18, 2022, on 32 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical ADGI trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 1.82%
Wide Bands Range Expansion 1.82%
Oversold Stochastic Weakness 1.82%
Stochastic Buy Signal Bullish -1.75%
Narrow Range Bar Range Contraction -1.75%
New 52 Week Low Weakness -1.75%
Wide Bands Range Expansion -1.75%
Oversold Stochastic Weakness -1.75%
New 52 Week Closing Low Bearish 6.46%
Expansion Breakdown Bearish Swing Setup 6.46%
Older End-of-Day Signals for ADGI ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 2 % about 2 hours ago
Down 1% about 2 hours ago
Up 2% about 2 hours ago
Up 1% about 2 hours ago
60 Minute Opening Range Breakdown about 20 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Adagio Therapeutics, Inc. Description

Adagio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Immunology Infectious Diseases Immune System Antibodies Monoclonal Antibody Antibody Antibody Solutions Neutralizing Antibody

Is ADGI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 78.82
52 Week Low 4.92
Average Volume 9,620,132
200-Day Moving Average 0.00
50-Day Moving Average 18.56
20-Day Moving Average 7.25
10-Day Moving Average 6.02
Average True Range 2.42
ADX 11.68
+DI 26.41
-DI 29.69
Chandelier Exit (Long, 3 ATRs) 9.84
Chandelier Exit (Short, 3 ATRs) 12.18
Upper Bollinger Bands 10.20
Lower Bollinger Band 4.31
Percent B (%b) 0.2
BandWidth 81.18
MACD Line -4.20
MACD Signal Line -4.81
MACD Histogram 0.6096
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.42
Resistance 3 (R3) 6.45 6.17 6.26
Resistance 2 (R2) 6.17 5.94 6.16 6.21
Resistance 1 (R1) 5.84 5.80 6.01 5.81 6.16
Pivot Point 5.56 5.56 5.65 5.55 5.56
Support 1 (S1) 5.23 5.33 5.40 5.20 4.84
Support 2 (S2) 4.95 5.19 4.94 4.79
Support 3 (S3) 4.62 4.95 4.74
Support 4 (S4) 4.59